Last reviewed: July 16, 2026. This article is for general information and does not replace advice from a licensed clinician.
Editorial review and sources
Editorial review: osvilt.com Editorial Team
Last reviewed: July 16, 2026
This medical article is based on current public medical sources and follows the osvilt.com Medical Review Policy. It is for general information only and does not replace professional care; see our Medical Disclaimer.
Motilium is a brand of domperidone in many countries. Cerucal is a brand of metoclopramide. Both are dopamine-antagonist antiemetic/prokinetic medicines, but they have different regulatory status and serious safety concerns.
Short answer: There is no universal ‘better’ choice. Domperidone is restricted or not approved in some countries because of heart rhythm risks, while metoclopramide carries a boxed warning for tardive dyskinesia and should generally not be used long term. The cause of nausea matters.
What changed in this update
The article now treats these as prescription-risk medicines rather than interchangeable nausea tablets. It adds FDA/EMA safety context, duration limits and red flags.
Side-by-side comparison
| Point | Motilium / domperidone | Cerucal / metoclopramide |
|---|---|---|
| Main action | Dopamine antagonist with antiemetic/prokinetic effects; less central nervous system penetration than metoclopramide. | Dopamine antagonist with antiemetic/prokinetic effects; more central nervous system adverse-effect concern. |
| Major safety issue | QT prolongation, dangerous arrhythmias, cardiac arrest and sudden death risk in susceptible users. | Tardive dyskinesia, dystonia, akathisia, sedation and other neurologic effects. |
| Regulatory context | Not approved for human use in the U.S.; restricted in Europe for nausea/vomiting with heart-risk precautions. | FDA-approved for selected indications but boxed warning advises avoiding treatment beyond 12 weeks. |
| Do not use casually with | QT-prolonging drugs, strong CYP3A4 inhibitors or known rhythm disorders. | Other dopamine blockers, Parkinson disease concerns, bowel obstruction/bleeding, seizure risk without review. |
Why domperidone is not just a gentler option
FDA states domperidone is not approved in the United States for human use and has been associated with serious cardiac adverse events. EMA restricted domperidone use because of concerns about dangerously irregular heartbeats in some patients.
Why metoclopramide is not a long-term default
DailyMed labeling warns that metoclopramide can cause tardive dyskinesia, a serious movement disorder that may be irreversible, and recommends avoiding use for longer than 12 weeks because risk increases with duration and cumulative dose.
Before choosing an antiemetic
Nausea and vomiting can come from migraine, pregnancy, medication effects, foodborne illness, bowel obstruction, gallbladder disease, pancreatitis, diabetes-related gastroparesis, intracranial problems or cardiac disease. Treating symptoms without diagnosis can be unsafe when red flags are present.
When to get medical care
Seek urgent care for chest pain, fainting, palpitations, severe dehydration, blood in vomit, black stool, severe abdominal pain, stiff neck, confusion, severe headache, neurologic symptoms, pregnancy with persistent vomiting, suspected poisoning, bowel obstruction symptoms, or involuntary movements after metoclopramide.
FAQ
Is Motilium safer than Cerucal?
Not automatically. Domperidone has important heart rhythm risks and is not approved for human use in the U.S.
Is Cerucal safe for long-term nausea?
Long-term use is limited by tardive dyskinesia risk. A clinician should reassess the cause and alternatives.
Can I take them together?
Do not combine dopamine-antagonist antiemetics unless a clinician specifically directs it.
